Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company

Business Wire May 11, 2015

Pfizer Appoints New Leaders for BioTherapeutics Research & Development and Rinat

Business Wire May 6, 2015

ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

PR Newswire May 6, 2015

Hospira Reports First-Quarter 2015 Results

PR Newswire April 28, 2015

PFIZER REPORTS FIRST-QUARTER 2015 RESULTS

Business Wire April 28, 2015

China Jo-Jo Drugstore Signed a New Sales Incentive Agreement with Wyeth Pharmaceutical, a Subsidiary of Pfizer

PR Newswire April 27, 2015

Pfizer Hosts Annual Meeting Of Shareholders

Business Wire April 23, 2015

Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI® (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer

Business Wire April 21, 2015

Nodality Publishes Study Results Confirming the Company's Diagnostic Can Predict Induction Therapy Response in Elderly Patients with Acute Myeloid Leukemia

Business Wire April 21, 2015

Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Business Wire April 21, 2015

Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders

Business Wire April 16, 2015

Pfizer Launches 2014 Integrated Annual Review

Business Wire April 16, 2015

Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

Business Wire April 15, 2015

Pfizer Launches First Annual PCSK9 Competitive Grants Program to Advance Cardiovascular Disease Research

Business Wire April 9, 2015

Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)

Business Wire April 7, 2015

Kathrin U. Jansen, Ph.D., to Lead Pfizer's Vaccine Research and Development Unit

Business Wire April 6, 2015

Nodality Launches PathPro(TM) Chronic Lymphocytic Leukemia (CLL) Panels Based on Leading Single Cell Network Profiling (SCNPTM) Platform to Enhance Pharmaceutical R&D

Business Wire April 2, 2015

Pharmaceutical-Biotech Industry Places 29 North American Manufacturing Plants on Chopping Block, an Industrial Info News Alert

Marketwired March 31, 2015

Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology Research Unit

Business Wire March 30, 2015

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Business Wire March 26, 2015